CCL5 and breast cancer: , gastric cancer (GC), breast cancer, glioblastoma multiforme, and CRC), through the recruitment of TAMs and their polarization toward a M2-like phenotype.577–580 Maraviroc, a specific CCR5 antagonist, was demonstrated to reduce the infiltration of monocytes/macrophages in breast cancer, GC, glioblastoma, and advanced CRC.577,581,582 Therefore, the CCL5-CCR5 axis might be another chemokine pathway with potential for preventing the recruitment of macrophages.